Drugs / WJ01075
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05470933 | Aug 2022 → Apr 2023 | cancer | Suzhou Junjing BioSciences Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WJ01075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470933 ↗ |
| Route | Oral | “Oral Dose Escalation” NCT05470933 ↗ |